191 related articles for article (PubMed ID: 32529264)
1. NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials.
Kapacee ZA; Knox JJ; Palmer D; Blagden SP; Lamarca A; Valle JW; McNamara MG
Med Oncol; 2020 Jun; 37(7):61. PubMed ID: 32529264
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer.
Arora M; Bogenberger JM; Abdelrahman A; Leiting JL; Chen X; Egan JB; Kasimsetty A; Lenkiewicz E; Malasi S; Uson PLS; Nagalo BM; Zhou Y; Salomao MA; Kosiorek HE; Braggio E; Barrett MT; Truty MJ; Borad MJ
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1063-1078. PubMed ID: 32440762
[TBL] [Abstract][Full Text] [Related]
3. NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121).
McNamara MG; Goyal L; Doherty M; Springfeld C; Cosgrove D; Sjoquist KM; Park JO; Verdaguer H; Braconi C; Ross PJ; Gramont A; Zalcberg JR; Palmer DH; Valle JW; Knox JJ
Future Oncol; 2020 Jun; 16(16):1069-1081. PubMed ID: 32374623
[TBL] [Abstract][Full Text] [Related]
4. A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08).
McNamara MG; Bridgewater J; Palmer DH; Faluyi O; Wasan H; Patel A; Ryder WD; Barber S; Gnanaranjan C; Ghazaly E; Evans TRJ; Valle JW
Oncologist; 2021 Apr; 26(4):e669-e678. PubMed ID: 33210382
[TBL] [Abstract][Full Text] [Related]
5. Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031.
Sarr A; Bré J; Um IH; Chan TH; Mullen P; Harrison DJ; Reynolds PA
Sci Rep; 2019 May; 9(1):7643. PubMed ID: 31113993
[TBL] [Abstract][Full Text] [Related]
6. A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer.
Kazmi F; Nicum S; Roux RL; Spiers L; Gnanaranjan C; Sukumaran A; Gabra H; Ghazaly E; McCracken NW; Harrison DJ; Blagden SP
Clin Cancer Res; 2021 Jun; 27(11):3028-3038. PubMed ID: 33741651
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
8. Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development.
Slusarczyk M; Lopez MH; Balzarini J; Mason M; Jiang WG; Blagden S; Thompson E; Ghazaly E; McGuigan C
J Med Chem; 2014 Feb; 57(4):1531-42. PubMed ID: 24471998
[TBL] [Abstract][Full Text] [Related]
9. A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
Davis EJ; Griffith KA; Kim EJ; Ruch JM; McDonnell KJ; Zalupski MM
Am J Clin Oncol; 2018 Feb; 41(2):128-132. PubMed ID: 26535993
[TBL] [Abstract][Full Text] [Related]
10. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ
BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981
[TBL] [Abstract][Full Text] [Related]
11. A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).
Kanai M; Hatano E; Kobayashi S; Fujiwara Y; Marubashi S; Miyamoto A; Shiomi H; Kubo S; Ikuta S; Yanagimoto H; Terajima H; Ikoma H; Sakai D; Kodama Y; Seo S; Morita S; Ajiki T; Nagano H; Ioka T
Cancer Chemother Pharmacol; 2015 Feb; 75(2):293-300. PubMed ID: 25477010
[TBL] [Abstract][Full Text] [Related]
12. Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer.
Furuse J; Okusaka T; Bridgewater J; Taketsuna M; Wasan H; Koshiji M; Valle J
Crit Rev Oncol Hematol; 2011 Oct; 80(1):31-9. PubMed ID: 21094052
[TBL] [Abstract][Full Text] [Related]
13. Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin.
Dierks J; Gaspersz MP; Belkouz A; van Vugt JLA; Coelen RJS; de Groot JWB; Ten Tije AJ; Meijer WG; Pruijt JFM; van Voorthuizen T; van Spronsen DJ; Rentinck M; Ten Oever D; Smit JM; Otten HM; van Gulik TM; Wilmink JW; Groot Koerkamp B; Klümpen H
Acta Oncol; 2018 Jun; 57(6):807-812. PubMed ID: 29265948
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
[TBL] [Abstract][Full Text] [Related]
15. Possibility of immunotherapy for biliary tract cancer: how do we prove efficacy? Introduction to a current ongoing phase I and randomized phase II study to evaluate the efficacy and safety of adding Wilms tumor 1 peptide vaccine to gemcitabine and cisplatin for the treatment of advanced biliary tract cancer (WT-BT trial).
Okusaka T; Ueno M; Sato T; Heike Y
J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):314-8. PubMed ID: 22273718
[TBL] [Abstract][Full Text] [Related]
16. Review of gemcitabine in biliary tract carcinoma.
Scheithauer W
Semin Oncol; 2002 Dec; 29(6 Suppl 20):40-5. PubMed ID: 12577232
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study.
Blagden SP; Rizzuto I; Suppiah P; O'Shea D; Patel M; Spiers L; Sukumaran A; Bharwani N; Rockall A; Gabra H; El-Bahrawy M; Wasan H; Leonard R; Habib N; Ghazaly E
Br J Cancer; 2018 Oct; 119(7):815-822. PubMed ID: 30206366
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancer.
Roth JA; Carlson JJ
J Gastrointest Cancer; 2012 Jun; 43(2):215-23. PubMed ID: 21234709
[TBL] [Abstract][Full Text] [Related]
19. NUC-1031 in biliary tract cancer: from bench to bedside and back?
Boyd LNC; Peters GJ; Kazemier G; Giovannetti E
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1011-1014. PubMed ID: 32476108
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study.
Feng K; Liu Y; Zhao Y; Yang Q; Dong L; Liu J; Li X; Zhao Z; Mei Q; Han W
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32487569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
